2023 World Coagulation Testing Market in 98 Countries-Hemostasis Analyzers and Consumables-2022 Supplier Shares, 2022-2027 Segment Volume and Sales Forecasts for over 40 Coagulation Assays, Opportunities for Suppliers-Molecular, Chromogenic and Immunodiagnostic Hemostasis Tests-Growth Strategies, Latest Technologies, Instrumentation Pipeline
This new 98-country survey from LeadingMarketResearch.com provides granular data and analysis not available from any other source.
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Rationale
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, IT and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Lupus Anticoagulants, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Sickle Cell, TEG, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America
Canada, Mexico, USA
Sales and Market Share Analysis
Sales and market shares of instrument and reagent suppliers in major countries.
Competitive Assessments
Extensive strategic profiles of major suppliers and emerging market entrants.
Market Segmentation Analysis
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Rationale
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, IT and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Lupus Anticoagulants, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Sickle Cell, TEG, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America
Canada, Mexico, USA
Sales and Market Share Analysis
Sales and market shares of instrument and reagent suppliers in major countries.
Competitive Assessments
Extensive strategic profiles of major suppliers and emerging market entrants.
Market Segmentation Analysis
- Comprehensive market segmentation analysis in major countries, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices
- Ambulatory Care Centers
- Test volume forecasts for over 40 major procedures.
- Review of established and emerging procedures.
- Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.
- Analysis of current and emerging technologies and their potential market applications.
- Companies developing or marketing new technologies and products by test.
- Product development and business expansion opportunities with significant market appeal.
- “Ideal” product models with tentative prices and operating characteristics.
- Alternative market penetration strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.
I. INTRODUCTION
II. WORLDWIDE MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. MARKET AND TECHNOLOGY OVERVIEW
A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrand's Factor
B. Coagulation Instrumentation Review: Centralized And POC Testing Analyzers
C. Major Coagulation Testing Technologies And Their Potential Applications
VIII. COUNTRY MARKET ANALYSES: BLOOD TYPING, GROUPING AND INFECTIOUS DISEASE SCREENING TEST VOLUME AND SALES FORECASTS FOR 98 COUNTRIES:
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE ASSESSMENTS
The report provides strategic assessments of over 20 leading coagulation market players and start-up companies with innovative technologies and products, including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratories
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others
II. WORLDWIDE MARKET OVERVIEW
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. MARKET AND TECHNOLOGY OVERVIEW
A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrand's Factor
B. Coagulation Instrumentation Review: Centralized And POC Testing Analyzers
C. Major Coagulation Testing Technologies And Their Potential Applications
VIII. COUNTRY MARKET ANALYSES: BLOOD TYPING, GROUPING AND INFECTIOUS DISEASE SCREENING TEST VOLUME AND SALES FORECASTS FOR 98 COUNTRIES:
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE ASSESSMENTS
The report provides strategic assessments of over 20 leading coagulation market players and start-up companies with innovative technologies and products, including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratories
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others
